bits and pieces , page-13

Interesting to know which of my 'claims' you think have been refuted. As far as I can see, there haven't been any partnerships announced between Biotron and a large Pharma company based on the so-called world beating results over the past couple of years. In that time sofosbuvir has completed phase 3 trials and is licensed for use in the US, and the once daily sofosbuvir/ledipasvir combination pill will be as well shortly. All I can see to this point is that BIT225 seems to work reasonably well in relatively easy to treat cohorts of patients. The HCV coinfected results appear more impressive although I haven't had a proper look yet. Going by their recent financials I imagine a capital raising is nearby.